FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971724397> ?p ?o ?g. }

• W2971724397 abstract "Background Using hypofractionation (fewer, larger doses of daily radiation) to treat localized prostate cancer may improve convenience and resource use. For hypofractionation to be feasible, it must be at least as effective for cancer‐related outcomes and have comparable toxicity and quality of life outcomes as conventionally fractionated radiation therapy. Objectives To assess the effects of hypofractionated external beam radiation therapy compared to conventionally fractionated external beam radiation therapy for men with clinically localized prostate cancer. Search methods We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid) and trials registries from 1946 to 15 March 2019 with reference checking, citation searching and contact with study authors. Searches were not limited by language or publication status. We reran all searches within three months (15th March 2019) prior to publication. Selection criteria Randomized controlled comparisons which included men with clinically localized prostate adenocarcinoma where hypofractionated radiation therapy (external beam radiation therapy) to the prostate using hypofractionation (greater than 2 Gy per fraction) compared with conventionally fractionated radiation therapy to the prostate delivered using standard fractionation (1.8 Gy to 2 Gy per fraction). Data collection and analysis We used standard Cochrane methodology. Two authors independently assessed trial quality and extracted data. We used Review Manager 5 for data analysis and meta‐analysis. We used the inverse variance method and random‐effects model for data synthesis of time‐to‐event data with hazard ratios (HR) and 95% confidence intervals (CI) reported. For dichotomous data, we used the Mantel‐Haenzel method and random‐effects model to present risk ratios (RR) and 95% CI. We used GRADE to assess evidence quality for each outcome. Main results We included 10 studies with 8278 men in our analysis comparing hypofractionation with conventional fractionation to treat prostate cancer. Primary outcomes Hypofractionation may result in little or no difference in prostate cancer‐specific survival [PC‐SS] (HR 1.00, 95% CI 0.72 to 1.39; studies = 8, participants = 7946; median follow‐up 72 months; low‐certainty evidence). For men in the intermediate‐risk group undergoing conventional fractionation this corresponds to 976 per 1000 men alive after 6 years and 0 more (44 fewer to 18 more) alive per 1000 men undergoing hypofractionation. We are uncertain about the effect of hypofractionation on late radiation therapy gastrointestinal (GI) toxicity (RR 1.10, 95% CI 0.68 to 1.78; studies = 4, participants = 3843; very low‐certainty evidence). Hypofractionation probably results in little or no difference to late radiation therapy genitourinary (GU) toxicity (RR 1.05, 95% CI 0.93 to 1.18; studies = 4, participants = 3843; moderate‐certainty evidence). This corresponds to 262 per 1000 late GU radiation therapy toxicity events with conventional fractionation and 13 more (18 fewer to 47 more) per 1000 men when undergoing hypofractionation. Secondary outcomes Hypofractionation results in little or no difference in overall survival (HR 0.94, 95% CI 0.83 to 1.07; 10 studies, 8243 participants; high‐certainty evidence). For men in the intermediate‐risk group undergoing conventional fractionation this corresponds to 869 per 1000 men alive after 6 years and 17 fewer (54 fewer to 17 more) participants alive per 1000 men when undergoing hypofractionation. Hypofractionation may result in little to no difference in metastasis‐free survival (HR 1.07, 95% CI 0.65 to 1.76; 5 studies, 4985 participants; low‐certainty evidence). This corresponds to 981 men per 1000 men metastasis‐free at 6 years when undergoing conventional fractionation and 5 more (58 fewer to 19 more) metastasis‐free per 1000 when undergoing hypofractionation. Hypofractionation likely results in a small, possibly unimportant reduction in biochemical recurrence‐free survival based on Phoenix criteria (HR 0.88, 95% CI 0.68 to 1.13; studies = 5, participants = 2889; median follow‐up 90 months to 108 months; moderate‐certainty evidence). In men of the intermediate‐risk group, this corresponds to 804 biochemical‐recurrence free men per 1000 participants at six years with conventional fractionation and 42 fewer (134 fewer to 37 more) recurrence‐free men per 1000 participants with hypofractionation Hypofractionation likely results in little to no difference to acute GU radiation therapy toxicity (RR 1.03, 95% CI 0.95 to 1.11; 4 studies, 4174 participants at 12 to 18 weeks' follow‐up; moderate‐certainty evidence). This corresponds to 360 episodes of toxicity per 1000 participants with conventional fractionation and 11 more (18 fewer to 40 more) per 1000 when undergoing hypofractionation. Authors' conclusions These findings suggest that moderate hypofractionation (up to a fraction size of 3.4 Gy) results in similar oncologic outcomes in terms of disease‐specific, metastasis‐free and overall survival. There appears to be little to no increase in both acute and late toxicity." @default.
• W2971724397 created "2019-09-12" @default.
• W2971724397 creator A5017131370 @default.
• W2971724397 creator A5042802288 @default.
• W2971724397 creator A5062128399 @default.
• W2971724397 creator A5076996294 @default.
• W2971724397 creator A5083796002 @default.
• W2971724397 date "2019-09-02" @default.
• W2971724397 modified "2023-09-26" @default.
• W2971724397 title "Hypofractionation for clinically localized prostate cancer" @default.
• W2971724397 cites W1247968195 @default.
• W2971724397 cites W1581993345 @default.
• W2971724397 cites W1789162631 @default.
• W2971724397 cites W1830334259 @default.
• W2971724397 cites W1858763784 @default.
• W2971724397 cites W1939466257 @default.
• W2971724397 cites W1964245721 @default.
• W2971724397 cites W1965897584 @default.
• W2971724397 cites W1966659026 @default.
• W2971724397 cites W1970398327 @default.
• W2971724397 cites W1973462147 @default.
• W2971724397 cites W1973914781 @default.
• W2971724397 cites W1980789427 @default.
• W2971724397 cites W1983228790 @default.
• W2971724397 cites W1984682601 @default.
• W2971724397 cites W1987470170 @default.
• W2971724397 cites W1989098069 @default.
• W2971724397 cites W1989762435 @default.
• W2971724397 cites W1990510898 @default.
• W2971724397 cites W1991048589 @default.
• W2971724397 cites W1992487094 @default.
• W2971724397 cites W1993681878 @default.
• W2971724397 cites W1996133043 @default.
• W2971724397 cites W1997716779 @default.
• W2971724397 cites W1999478846 @default.
• W2971724397 cites W2001616768 @default.
• W2971724397 cites W2003218091 @default.
• W2971724397 cites W2003895274 @default.
• W2971724397 cites W2004909463 @default.
• W2971724397 cites W2006175454 @default.
• W2971724397 cites W2006833788 @default.
• W2971724397 cites W2007473361 @default.
• W2971724397 cites W2008090769 @default.
• W2971724397 cites W2008118429 @default.
• W2971724397 cites W2011204537 @default.
• W2971724397 cites W2011335777 @default.
• W2971724397 cites W2015981950 @default.
• W2971724397 cites W2016103128 @default.
• W2971724397 cites W2020242089 @default.
• W2971724397 cites W2021687564 @default.
• W2971724397 cites W2022936635 @default.
• W2971724397 cites W2023807811 @default.
• W2971724397 cites W2025488348 @default.
• W2971724397 cites W2033942571 @default.
• W2971724397 cites W2035632263 @default.
• W2971724397 cites W2037730131 @default.
• W2971724397 cites W2040755747 @default.
• W2971724397 cites W2042484962 @default.
• W2971724397 cites W2043945205 @default.
• W2971724397 cites W2044740238 @default.
• W2971724397 cites W2046391772 @default.
• W2971724397 cites W2047842438 @default.
• W2971724397 cites W2050744051 @default.
• W2971724397 cites W2059842435 @default.
• W2971724397 cites W2061573012 @default.
• W2971724397 cites W2061988762 @default.
• W2971724397 cites W2063137562 @default.
• W2971724397 cites W2071365490 @default.
• W2971724397 cites W2073229943 @default.
• W2971724397 cites W2073988927 @default.
• W2971724397 cites W2075642745 @default.
• W2971724397 cites W2078064304 @default.
• W2971724397 cites W2078753880 @default.
• W2971724397 cites W2079878657 @default.
• W2971724397 cites W2081704383 @default.
• W2971724397 cites W2084279317 @default.
• W2971724397 cites W2086240335 @default.
• W2971724397 cites W2088021312 @default.
• W2971724397 cites W2088095316 @default.
• W2971724397 cites W2093867637 @default.
• W2971724397 cites W2097532477 @default.
• W2971724397 cites W2099051717 @default.
• W2971724397 cites W2104592191 @default.
• W2971724397 cites W2104631398 @default.
• W2971724397 cites W2108116635 @default.
• W2971724397 cites W2109146014 @default.
• W2971724397 cites W2111180711 @default.
• W2971724397 cites W2111545393 @default.
• W2971724397 cites W2115675646 @default.
• W2971724397 cites W2117728681 @default.
• W2971724397 cites W2117792530 @default.
• W2971724397 cites W2118044567 @default.
• W2971724397 cites W2119605658 @default.
• W2971724397 cites W2121407352 @default.
• W2971724397 cites W2122326560 @default.
• W2971724397 cites W2125435699 @default.
• W2971724397 cites W2126930838 @default.
• W2971724397 cites W2130514725 @default.
• W2971724397 cites W2131398800 @default.
• W2971724397 cites W2137880005 @default.

• next